29 results on '"Sparks, J"'
Search Results
2. AB0270 DESIGN OF A PROSPECTIVE MULTI-NATIONAL CROSS-SECTIONAL STUDY ON SCREENING FOR INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) GUIDED BY RISK FACTORS
3. POS1055 ASSOCIATIONS AND MORTALITY IMPACT OF MACHINE LEARNING-DERIVED QUANTITATIVE PARENCHYMAL LUNG COMPUTED TOMOGRAPHY FEATURES IN RHEUMATOID ARTHRITIS AND NON-RA COMPARATORS IN A MULTICENTER PROSPECTIVE COHORT OF SMOKERS
4. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor- associated arthritis.
5. POS0402 CLONALLY EXPANDED CD38hi CYTOTOXIC CD8 T CELLS DEFINE THE T CELL INFILTRATE IN CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS
6. POS0062 A RISK SCORE TO DETECT SUBCLINICAL RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
7. POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS
8. POS1234 DMARD DISRUPTION, INCREASED DISEASE ACTIVITY, AND PROLONGED SYMPTOM DURATION AFTER ACUTE COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE STUDY
9. AB1039 PATIENT REPORTED OUTCOMES AMONG PATIENTS RECEIVING TREATMENT FROM THE PEGLOTICASE PHASE 3 CLINICAL TRIALS FOR UNCONTROLLED GOUT
10. AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY
11. OP0251 IMPACT OF INTERSTITIAL LUNG DISEASE ON SEVERE COVID-19 OUTCOMES FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTICENTER STUDY
12. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)
13. POS1174 HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY
14. POS0051 THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY
15. AB0674 RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY
16. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY
17. POS0522 PREVALENCE OF BRONCHIECTASIS IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
18. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE
19. POS0219 EFFECT OF LOW-DOSE METHOTREXATE ON ESTIMATED GLOMERULAR FILTRATION RATE AND KIDNEY ADVERSE EVENTS IN THE CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL
20. OP0111 RHEUMATOID ARTHRITIS SEROLOGIC PHENOTYPE AT DIAGNOSIS AND SUBSEQUENT RISK FOR PNEUMONIA IDENTIFIED USING MACHINE LEARNING APPROACHES
21. TO EACH THEIR OWN-CLASSIFICATION OF ARTHRITIS PHENOTYPE AMONG INFLAMMATORY ARTHRITIS PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS.
22. COMPARATIVE SAFETY OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS FOR CARDIOVASCULAR AND CANCER OUTCOMES IN RHEUMATOID ARTHRITIS.
23. DESIGN OF A PROSPECTIVE MULTI-NATIONAL CROSS-SECTIONAL STUDY ON SCREENING FOR INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) GUIDED BY RISK FACTORS.
24. USING SURVIVAL CLASSIFICATION AND REGRESSION TREES AND SURVIVAL RANDOM FOREST TO INVESTIGATE ASSOCIATIONS AMONG FACTORS FOR CANCER PROGRESSION AND ARTHRITIS CONTROL IN A MULTI-CENTER RETROSPECTIVE COHORT OF PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS
25. ASSOCIATIONS AND MORTALITY IMPACT OF MACHINE LEARNING-DERIVED QUANTITATIVE PARENCHYMAL LUNG COMPUTED TOMOGRAPHY FEATURES IN RHEUMATOID ARTHRITIS AND NON-RA COMPARATORS IN A MULTICENTER PROSPECTIVE COHORT OF SMOKERS.
26. IMMUNOMODULATORY MEDICATIONS AND OUTCOMES OF PATIENTS WITH PRE-EXISTING RHEUMATOID ARTHRITIS USING IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCER.
27. CD38HI CYTOTOXIC CD8 T CELLS ARE EXPANDED FOLLOWING CHECKPOINT BLOCKADE AND CHARACTERIZE THE T CELL INFILTRATE IN CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS.
28. INCIDENCE RATES OF INTERSTITIAL LUNG DISEASE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: A POST HOC POOLED ANALYSIS FROM A COMPENDIUM OF CLINICAL TRIALS.
29. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.